Cargando…
Serial minimal residual disease (MRD) monitoring during first-line FCR treatment for CLL may direct individualized therapeutic strategies
Achieving undetectable MRD (U-MRD) status after chemoimmunotherapy predicts longer progression-free and overall survival. The predictive factors and timing of relapse in patients with U-MRD and value of interim MRD analysis are ill-defined. This was a prospective study of 289 patients with CLL treat...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6192870/ https://www.ncbi.nlm.nih.gov/pubmed/29769624 http://dx.doi.org/10.1038/s41375-018-0132-y |
_version_ | 1783363964357312512 |
---|---|
author | Thompson, Philip A. Peterson, Christine B. Strati, Paolo Jorgensen, Jeff Keating, Michael J. O’Brien, Susan M. Ferrajoli, Alessandra Burger, Jan A. Estrov, Zeev Jain, Nitin Kadia, Tapan M. Borthakur, Gautam DiNardo, Courtney D. Daver, Naval Jabbour, Elias Wierda, William G. |
author_facet | Thompson, Philip A. Peterson, Christine B. Strati, Paolo Jorgensen, Jeff Keating, Michael J. O’Brien, Susan M. Ferrajoli, Alessandra Burger, Jan A. Estrov, Zeev Jain, Nitin Kadia, Tapan M. Borthakur, Gautam DiNardo, Courtney D. Daver, Naval Jabbour, Elias Wierda, William G. |
author_sort | Thompson, Philip A. |
collection | PubMed |
description | Achieving undetectable MRD (U-MRD) status after chemoimmunotherapy predicts longer progression-free and overall survival. The predictive factors and timing of relapse in patients with U-MRD and value of interim MRD analysis are ill-defined. This was a prospective study of 289 patients with CLL treated first-line with FCR. MRD analysis was performed after course 3 (C3) and at end-of-therapy (EOT) in bone marrow using 4-color flow cytometry (sensitivity 10(−4)). Eighteen percent of patients had U-MRD after C3 and 48% at EOT. U-MRD status at EOT was associated with longer PFS (median NR vs 38mo, p<0.001). MRD level (≤1% vs. >1%) after C3 predicted greater likelihood of U-MRD status at EOT (64% vs. 9%, p<0.001). PFS was significantly longer for patients with MRD ≤1% vs. >1% after C3 (median 73mo vs 41mo, p<0.001), but similar for <0.01% vs. 0.01–1%. Interim MRD status may therefore be used for risk stratification and to individualize therapy. Eighty-five patients with U-MRD status at EOT had yearly blood MRD monitoring; MRD re-emerged in 38/85, a median of 48mo after EOT and preceded clinical progression by a median of 24 months, which may allow development of early intervention strategies. |
format | Online Article Text |
id | pubmed-6192870 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
record_format | MEDLINE/PubMed |
spelling | pubmed-61928702018-10-18 Serial minimal residual disease (MRD) monitoring during first-line FCR treatment for CLL may direct individualized therapeutic strategies Thompson, Philip A. Peterson, Christine B. Strati, Paolo Jorgensen, Jeff Keating, Michael J. O’Brien, Susan M. Ferrajoli, Alessandra Burger, Jan A. Estrov, Zeev Jain, Nitin Kadia, Tapan M. Borthakur, Gautam DiNardo, Courtney D. Daver, Naval Jabbour, Elias Wierda, William G. Leukemia Article Achieving undetectable MRD (U-MRD) status after chemoimmunotherapy predicts longer progression-free and overall survival. The predictive factors and timing of relapse in patients with U-MRD and value of interim MRD analysis are ill-defined. This was a prospective study of 289 patients with CLL treated first-line with FCR. MRD analysis was performed after course 3 (C3) and at end-of-therapy (EOT) in bone marrow using 4-color flow cytometry (sensitivity 10(−4)). Eighteen percent of patients had U-MRD after C3 and 48% at EOT. U-MRD status at EOT was associated with longer PFS (median NR vs 38mo, p<0.001). MRD level (≤1% vs. >1%) after C3 predicted greater likelihood of U-MRD status at EOT (64% vs. 9%, p<0.001). PFS was significantly longer for patients with MRD ≤1% vs. >1% after C3 (median 73mo vs 41mo, p<0.001), but similar for <0.01% vs. 0.01–1%. Interim MRD status may therefore be used for risk stratification and to individualize therapy. Eighty-five patients with U-MRD status at EOT had yearly blood MRD monitoring; MRD re-emerged in 38/85, a median of 48mo after EOT and preceded clinical progression by a median of 24 months, which may allow development of early intervention strategies. 2018-04-17 2018-11 /pmc/articles/PMC6192870/ /pubmed/29769624 http://dx.doi.org/10.1038/s41375-018-0132-y Text en Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use: http://www.nature.com/authors/editorial_policies/license.html#terms |
spellingShingle | Article Thompson, Philip A. Peterson, Christine B. Strati, Paolo Jorgensen, Jeff Keating, Michael J. O’Brien, Susan M. Ferrajoli, Alessandra Burger, Jan A. Estrov, Zeev Jain, Nitin Kadia, Tapan M. Borthakur, Gautam DiNardo, Courtney D. Daver, Naval Jabbour, Elias Wierda, William G. Serial minimal residual disease (MRD) monitoring during first-line FCR treatment for CLL may direct individualized therapeutic strategies |
title | Serial minimal residual disease (MRD) monitoring during first-line FCR treatment for CLL may direct individualized therapeutic strategies |
title_full | Serial minimal residual disease (MRD) monitoring during first-line FCR treatment for CLL may direct individualized therapeutic strategies |
title_fullStr | Serial minimal residual disease (MRD) monitoring during first-line FCR treatment for CLL may direct individualized therapeutic strategies |
title_full_unstemmed | Serial minimal residual disease (MRD) monitoring during first-line FCR treatment for CLL may direct individualized therapeutic strategies |
title_short | Serial minimal residual disease (MRD) monitoring during first-line FCR treatment for CLL may direct individualized therapeutic strategies |
title_sort | serial minimal residual disease (mrd) monitoring during first-line fcr treatment for cll may direct individualized therapeutic strategies |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6192870/ https://www.ncbi.nlm.nih.gov/pubmed/29769624 http://dx.doi.org/10.1038/s41375-018-0132-y |
work_keys_str_mv | AT thompsonphilipa serialminimalresidualdiseasemrdmonitoringduringfirstlinefcrtreatmentforcllmaydirectindividualizedtherapeuticstrategies AT petersonchristineb serialminimalresidualdiseasemrdmonitoringduringfirstlinefcrtreatmentforcllmaydirectindividualizedtherapeuticstrategies AT stratipaolo serialminimalresidualdiseasemrdmonitoringduringfirstlinefcrtreatmentforcllmaydirectindividualizedtherapeuticstrategies AT jorgensenjeff serialminimalresidualdiseasemrdmonitoringduringfirstlinefcrtreatmentforcllmaydirectindividualizedtherapeuticstrategies AT keatingmichaelj serialminimalresidualdiseasemrdmonitoringduringfirstlinefcrtreatmentforcllmaydirectindividualizedtherapeuticstrategies AT obriensusanm serialminimalresidualdiseasemrdmonitoringduringfirstlinefcrtreatmentforcllmaydirectindividualizedtherapeuticstrategies AT ferrajolialessandra serialminimalresidualdiseasemrdmonitoringduringfirstlinefcrtreatmentforcllmaydirectindividualizedtherapeuticstrategies AT burgerjana serialminimalresidualdiseasemrdmonitoringduringfirstlinefcrtreatmentforcllmaydirectindividualizedtherapeuticstrategies AT estrovzeev serialminimalresidualdiseasemrdmonitoringduringfirstlinefcrtreatmentforcllmaydirectindividualizedtherapeuticstrategies AT jainnitin serialminimalresidualdiseasemrdmonitoringduringfirstlinefcrtreatmentforcllmaydirectindividualizedtherapeuticstrategies AT kadiatapanm serialminimalresidualdiseasemrdmonitoringduringfirstlinefcrtreatmentforcllmaydirectindividualizedtherapeuticstrategies AT borthakurgautam serialminimalresidualdiseasemrdmonitoringduringfirstlinefcrtreatmentforcllmaydirectindividualizedtherapeuticstrategies AT dinardocourtneyd serialminimalresidualdiseasemrdmonitoringduringfirstlinefcrtreatmentforcllmaydirectindividualizedtherapeuticstrategies AT davernaval serialminimalresidualdiseasemrdmonitoringduringfirstlinefcrtreatmentforcllmaydirectindividualizedtherapeuticstrategies AT jabbourelias serialminimalresidualdiseasemrdmonitoringduringfirstlinefcrtreatmentforcllmaydirectindividualizedtherapeuticstrategies AT wierdawilliamg serialminimalresidualdiseasemrdmonitoringduringfirstlinefcrtreatmentforcllmaydirectindividualizedtherapeuticstrategies |